Abstract
Although antimicrobial resistance has had an enormous impact on selection and utilization of antibiotics in virtually all aspects of clinical medicine, both inpatient and community based, little attention has been directed at antimicrobial resistance occurring in vaginal infections. Little evidence exists that frequent relapses of bacterial vaginosis or vulvovaginal candidiasis are due to antimicrobial resistance. Similarly, metronidazole-resistant trichomoniasis remains rare. Nevertheless, abuse of overthe-counter antimycotics, as well as widespread prescription of systemic oral azoles, could result in spread of azole-resistant Candida albicans, and even more likely could lead to an increase in non-albicans Candida species with intrinsic azole resistance. Problematic species include Candida glabrata and rarely Candida krusei.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Blackwell AL, Fox AR, Phillips I, Barlow D: Anaerobic vaginosis (non-specific vaginitis): clinical, microbiological, and therapeutic findings. Lancet 1983, 2:1379–1382.
Hay P: Recurrent bacterial vaginosis. Curr Infect Dis Rep 2000, 2:506–512. Excellent overview of pathogenesis of recurrent bacterial vaginosis.
Bannatyne RM, Smith AM: Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis. Sex Transm Infect 1998, 74:455–456.
Tepper RS, Ives TJ, Kebede M: Recurrent bacterial vaginosis unresponsive to metronidazole: successful treatment with oral clindamycin. J Am Board Fam Pract 1994, 7:431–432.
Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995, 39:1–8.
Vanden Bossche H, Dromer F, Improvisi I, et al.: Antifungal drug resistance in pathogenic fungi. Med Mycol 1998, 36(Suppl 1):119–128.
Maenza JR, Merz WG, Romagnoli MJ, et al.: Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997, 24:28–34.
Goldman M, Cloud GA, Smedema M, et al.: Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? Antimicrob Agents Chemother 2000, 44:1585–1587.
Vazquez JA, Sobel JD, Peng G, et al.: Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Clin Infect Dis 1999, 28:1025–1031.
Groll AH, Piscitelli SC, Walsh TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. J Med Vet Mycol 1994, 32:267–274.
Sobel JD, Vazquez JA: Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996, 22:726–727.
Sobel JS, Kapernick PS, Zervos MJ, et al.: Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001, In press. A large prospective, randomized, controlled trial comparing dosage and duration of fluconazole therapy for recurrent Candida vaginitis. Importance of Candida species in influencing outcome of therapy emerged.
Sobel JD, Chaim W: Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin Infect Dis 1997, 24:649–652.
Sobel JD, Ohmit SE, Schuman P, et al.: The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001, 183:286–293. In a large cohort of HIV-seropositive women, monitoring of vaginal Candida colonization showed progressive acquisition of C. glabrata with reduced fluconazole susceptibility.
Fong IW, Bannatyne RM, Wong P: Lack of in vitro resistance of Candida albicans to ketoconazole, itraconazole and clotrimazole in women treated for recurrent vaginal candidiasis. Genitourin Med 1993, 69:44–46.
Lynch ME, Sobel JD: Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994, 32:267–274.
Lossick JG, Kent HL: Trichomoniasis: trends in diagnosis and management. Am J Obstet Gynecol 1991, 165:1217–1222.
Schmid G, Narcisi E, Mosure D, et al.: Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med 2001, 46:545–549.
Petrin D, Delgaty K, Bhatt R, Garber G: Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev 1998, 11:300–317.
Nyirjesy P, Sobel JD, Weitz MV, et al.: Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 1998, 26:986–988.
Perez S, Fernandez-Verdugo A, Perez F, Vazquez F: Prevalence of 5-nitroimidazole-resistant trichomonas vaginalis in Oviedo, Spain. Sex Transm Dis 2001, 28:115–116.
Nyirjesy P: Managing resistant trichomonas vaginitis. Curr Infect Dis Rep 1999, 1:389–392.
Sobel JD, Nyirjesy P, Brown W: Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis. Clin Infect Dis 2001, 33:1341–1346. Tinidazole oral and vaginal therapy was highly successful in curing metronidazole-resistant trichomoniasis.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sobel, J.D. Antimicrobial resistance in vulvovaginitis. Curr Infect Dis Rep 3, 546–549 (2001). https://doi.org/10.1007/s11908-001-0093-5
Issue Date:
DOI: https://doi.org/10.1007/s11908-001-0093-5